关于 "Cancer stem cell" 的结果2+ 个结果
筛选:PD-1/PD-L1 interaction×
- SintilimabCAS: 2072873-06-2
Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
PD-1/PD-L1 interaction - Nivolumab (BMS-936558)CAS: 946414-94-4
Nivolumab 是一种抗癌单克隆抗体，是一种程序性死亡受体-1 阻断人 IgG4 抗体，用于治疗晚期（转移性）非小细胞肺癌。
PD-1/PD-L1 interaction
| 货号 | 产品名称 | CAS号 | 靶点 / 通路 | 引用 | 结构 |
|---|---|---|---|---|---|
| GC65290 | Sintilimab | 2072873-06-2 | PD-1/PD-L1 interaction | ||
Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. | |||||
| GC34218 | Nivolumab (BMS-936558) | 946414-94-4 | PD-1/PD-L1 interaction | ||
Nivolumab 是一种抗癌单克隆抗体，是一种程序性死亡受体-1 阻断人 IgG4 抗体，用于治疗晚期（转移性）非小细胞肺癌。 | |||||